» Articles » PMID: 36271363

Impact of Hypoglycemia at the Time of Hospitalization for Heart Failure from Emergency Department on Major Adverse Cardiovascular Events in Patients with and Without Type 2 Diabetes

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Few studies have examined the association between hypoglycemic episodes among people with type 2 diabetes (T2DM) at the time of hospitalization for heart failure (HF) and cardiovascular outcomes.

Methods: From March 2016 to June 2018, we conducted a retrospective cohort study to investigate hypoglycemia during HF hospitalization in the emergency department, three-point major adverse cardiovascular events (3P-MACE), and all-cause mortality; these were followed up through June 2021. HF hospitalization was defined according to American Heart Association criteria. Hypoglycemia was defined as a glucose level < 3.9 mmol/L at the time of HF hospitalization. We classified the enrolled patients into three groups (reference group, those without T2DM or hypoglycemia; those diagnosed with T2DM without hypoglycemia; and those with hypoglycemia and T2DM). We used Cox proportional hazard regression analysis to investigate the association between the three groups and the development of the first occurrence of 3P-MACE and all-cause mortality.

Results: During a median of 25 months of follow-up, a total of 783 patients admitted due to HF were analyzed. In total, 159 (20.3%) cases of 3P-MACE were identified, and the mortality rate was 20.2% (n = 158). The median age of patients was 76.0 (65.0-82.0) years, and 49.0% were men. Patients with 3P-MACE had a lower body mass index (22.6 [20.4-25.1] vs. 23.8 [21.3-26.7]), higher frequency of previous history of HF (24.5% vs. 15.7%), T2DM (64.2% vs. 47.3%), higher rates of hypoglycemia at the time of HF hospitalization (19.5% vs. 7.7%), and lower eGFR levels (61.1 [36.0-80.7] mL/min/1.73 m vs. 69.2 [45.8-89.5] mL/min/1.73 m) than those without 3P-MACE. The multivariable adjusted HR of 3P-MACE was as follows: group with hypoglycemia and T2DM: HR, 2.29; 95% CI: 1.04-5.06; group with T2DM without hypoglycemia: HR: 1.42; 95% CI: 0.86-2.33; and all-cause mortality group with hypoglycemia and T2DM: HR: 2.58; 95% CI: 1.26-5.31, group with T2DM without hypoglycemia: HR: 1.32; 95% CI: 0.81-2.16; compared to the reference group (group without T2DM or hypoglycemia).

Conclusions: T2DM and hypoglycemia are independent risk factors for 3P-MACE and all-cause mortality compared to those without hypoglycemia during HF hospitalization.

Citing Articles

Impact of early CVP monitoring on 1-year mortality in patients with congestive heart failure in the ICU: a retrospective analysis based on the MIMIC-IV2.2 database.

Chen J, Que S, Jin G, Zhu Y, Ma B, Hu W BMC Cardiovasc Disord. 2025; 25(1):162.

PMID: 40055591 PMC: 11887090. DOI: 10.1186/s12872-025-04602-1.


The association between the stress hyperglycaemia ratio and mortality in cardiovascular disease: a meta-analysis and systematic review.

Esdaile H, Khan S, Mayet J, Oliver N, Reddy M, Shah A Cardiovasc Diabetol. 2024; 23(1):412.

PMID: 39550575 PMC: 11568630. DOI: 10.1186/s12933-024-02454-1.


The optimal blood glucose is significantly associated with lower mortality in critically ill patients with cardiogenic shock: an analysis revealed with time series blood glucose records.

Sun C, Zhou J, Huang Y, Ning Y, Xu X Eur J Med Res. 2024; 29(1):129.

PMID: 38368401 PMC: 10874009. DOI: 10.1186/s40001-024-01724-8.


A meta-analysis of the relationship between glycaemic variability and the mortality of patients with heart failure.

Fu X, Wei Y, Fang J ESC Heart Fail. 2024; 11(3):1305-1316.

PMID: 38243645 PMC: 11098637. DOI: 10.1002/ehf2.14627.


Association of hypoglycaemia with the risks of arrhythmia and mortality in individuals with diabetes - a systematic review and meta-analysis.

Li G, Zhong S, Wang X, Zhuge F Front Endocrinol (Lausanne). 2023; 14:1222409.

PMID: 37645418 PMC: 10461564. DOI: 10.3389/fendo.2023.1222409.

References
1.
Levey A, Eckardt K, Tsukamoto Y, Levin A, Coresh J, Rossert J . Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005; 67(6):2089-100. DOI: 10.1111/j.1523-1755.2005.00365.x. View

2.
Cavender M, Steg P, Smith Jr S, Eagle K, Ohman E, Goto S . Impact of Diabetes Mellitus on Hospitalization for Heart Failure, Cardiovascular Events, and Death: Outcomes at 4 Years From the Reduction of Atherothrombosis for Continued Health (REACH) Registry. Circulation. 2015; 132(10):923-31. DOI: 10.1161/CIRCULATIONAHA.114.014796. View

3.
Lee T, Chen J, Cohen D, Tsao L . The association between blood pressure and mortality in patients with heart failure. Am Heart J. 2005; 151(1):76-83. DOI: 10.1016/j.ahj.2005.03.009. View

4.
. 6. Glycemic Targets: . Diabetes Care. 2020; 44(Suppl 1):S73-S84. DOI: 10.2337/dc21-S006. View

5.
Kacheva S, Karges B, Goller K, Marx N, Mischke K, Karges W . QT prolongation caused by insulin-induced hypoglycaemia - An interventional study in 119 individuals. Diabetes Res Clin Pract. 2016; 123:165-172. DOI: 10.1016/j.diabres.2016.11.021. View